ESTRELLA IMMUNOPHARMA, INC. (ESLA) Operating income 2021–2025
ESTRELLA IMMUNOPHARMA, INC. (ESLA) annual operating income history from SEC filings — each fiscal year as reported.
-$13.1MFY2025 · since FY2021: -$249,146 → -$13.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$13.1M | — |
| FY2023 | -$7.3M | +34.2% |
| FY2022 | -$11.1M | -4361.0% |
| FY2021 | -$249,146 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ESLA financial trends
ESLA RevenueESLA Net incomeESLA Net marginESLA Gross profitESLA Gross marginESLA Operating marginESLA Operating cash flowESLA Free cash flowESLA Capital expendituresESLA Return on equityESLA Stock buybacksESLA Dividends paidESLA Total assetsESLA Total liabilitiesESLA Shareholders’ equityESLA overview →